|
Miraculins Inc. (TSX-V:MOM), a Canadian medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs and Diagnostic Technologies Ltd. (DTL), an Israel based developer of diagnostic kits and devices for monitoring pregnancies at risk are pleased to announce they have been notified by the CIIRDF (Canada-Israel Industrial Research and Development Foundation) of the approval of $782,000 in grant funding, over a two year period, for a joint research and development project.
Read More
|
|
WINNIPEG, Manitoba – May 19, 2010 – Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce that it has engaged CHF Investor Relations (Cavalcanti Hume Funfer Inc., “CHF”), a well established Canadian Investor Relations firm headquartered in Toronto and operating under the same management for the past seventeen years.
Read More
|
|
WINNIPEG, Manitoba – March 22, 2010 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, announces today an amendment to the terms of its private placement offering (the "Offering") announced on February 9, 2010. The Company is amending the Offering to sell up to 10,000,000 units ("Units") at a price of $0.05 per Unit for gross proceeds of up to $500,000.
Read More
|
|
Miraculins CEO Christopher J. Moreau recently told the Company's story to Leonard Zehr from Biotuesday.ca and the conversation can be found here:
http://biotuesday.ca/2010/03/02/in-conversation-with-christopher-moreau/
Read More
|
|
WINNIPEG, Manitoba – February 9, 2010 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, today announces a non-brokered private placement offering (the “Offering”) of up to 7,150,000 units (“Units”) at a price of $0.07 per Unit for gross proceeds of up to $500,500. Each Unit will be comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a “Warrant”).
Read More
|
|
|